Myung In Pharmaceutical LTD. (KRX:317450)

South Korea flag South Korea · Delayed Price · Currency is KRW
63,000
-3,200 (-4.83%)
At close: Mar 3, 2026
-47.41%
Market Cap 919.80B
Revenue (ttm) 283.31B
Net Income (ttm) 72.18B
Shares Out 14.60M
EPS (ttm) 6,407.02
PE Ratio 9.83
Forward PE n/a
Dividend 1,500.00 (2.27%)
Ex-Dividend Date Dec 29, 2025
Volume 58,412
Average Volume 52,392
Open 64,900
Previous Close 66,200
Day's Range 63,000 - 65,600
52-Week Range 57,800 - 134,500
Beta n/a
RSI 47.83
Earnings Date Mar 31, 2026

About KRX:317450

Myung In Pharmaceutical LTD., a pharmaceutical company, manufactures ETC and OTC drugs. It offers products in the areas of thrombosis and anti-platelet, anti-hypertensive, anti-angina, anti-parkinson, anti-dementia, anti-epileptics, anti-schizophrenia, anti-depressants, adhd, anti-insomnia, gum disease treatment, gastrointestinal, cold-cough medicine, anti-fever, anti-pain, anti-inflammation agent, nutrition supplements and other pharmaceuticals. The company also provides APIs, such as benztropine mesylate, benidipine hcl, clopidogrel bisulfate... [Read more]

Industry Pharmaceutical Preparations
Founded 1985
Employees 335
Stock Exchange Korea Stock Exchange
Ticker Symbol 317450
Full Company Profile

Financial Performance

In 2024, KRX:317450's revenue was 269.43 billion, an increase of 11.18% compared to the previous year's 242.34 billion. Earnings were 68.67 billion, a decrease of -7.84%.

Financial Statements

News

There is no news available yet.